We aimed to develop a novel, accessible, and sensitive model for detecting LAS using OCT/OCTA Methods: Patients diagnosed with LAS and healthy controls were included
Larger cohorts for training of the model, external testing and examination of its general utility for supporting decision-making when clinical examination is not possible are warranted
How Tirzepatide Works Mimics GLP-1 and GIP hormones to improve insulin response Reduces appetite and food intake Slows gastric emptying, increasing feelings of fullness Helps regulate blood sugar while promoting weight loss Benefits of Tirzepatide Significant weight loss reported in clinical trials, sometimes over 20% of body weight Improves blood sugar control for people with diabetes or prediabetes Reduces risk factors related to obesity such as high blood pressure and cholesterol Administered once weekly via injection, convenient dosing Limitations and Considerations Possible side effects include nausea, diarrhea, and vomiting, especially early in treatment Prescription medication requiring medical supervision Not suitable for people with certain medical conditions Cost and insurance coverage may be limiting factors Comparing AOD 9604 and Tirzepatide | Feature | AOD 9604 | Tirzepatide | |------------------------|---------------------------------|--------------------------------| | Origin | Peptide fragment of growth hormone | Synthetic dual hormone agonist | | Primary use | Fat metabolism and weight management | Type 2 diabetes and weight loss | | Mechanism | Stimulates fat breakdown, inhibits fat creation | Regulates appetite and insulin | | Administration | Injection or nasal spray (varies) | Weekly injection | | Weight loss potential | Moderate, supports fat loss | High, up to 20%+ body weight | | Side effects | Minimal, mostly mild | Gastrointestinal symptoms common| | Approval status | Limited regulatory approval | FDA approved for diabetes and weight loss | | Cost | Generally lower | Higher, prescription required | Who Should Consider AOD 9604
increasing it, with more
CA A Cancer J Clin
